Wolverine blend

The Wolverine blend is a two-peptide research formulation combining BPC-157 and TB-500 in a 1:1 ratio, sold strictly for research use only. The name is also used loosely for a larger clinical protocol, so the first thing to verify is which one a vial actually is — and the per-component lab data above shows exactly what's inside.

What is the Wolverine blend and what's in it?

The Wolverine blend is a two-peptide research vial combining BPC-157 and TB-500 (Thymosin Beta-4) in a 1:1 ratio, most commonly 10 mg or 20 mg total, sold for research use only. The name — borrowed from the comic-book character known for rapid healing — is a community label, not a clinical designation. One important disambiguation: some clinics use "Wolverine stack" for a four-peptide protocol that adds CJC-1295 and Ipamorelin to the base pair. The product sold as a single Wolverine vial is the two-peptide version.

The two components, and what each contributes:

The rationale for pairing them is that they act on non-overlapping parts of the same problem — BPC-157 primarily at the local injury site, TB-500 more systemically — which is why the combination anchors the tissue repair peptide category.

What does the research show for BPC-157 and TB-500?

No controlled clinical trial of the BPC-157 + TB-500 combination has been published as of August 2026 — the pairing's rationale comes from single-compound research, most of it preclinical. BPC-157 is supported by more than 100 preclinical studies, predominantly from Prof. Predrag Sikirić's group at the University of Zagreb, starting with the 1993 foundational paper documenting tissue-protective effects; a 2025 orthopaedic systematic review found only one clinical study met inclusion criteria among 544 screened (evidence level: preclinical; no human RCTs). TB-500 itself has preclinical wound-healing and cell-migration data only — the one first-in-human Phase 1 safety trial in this family tested recombinant thymosin β4, the full parent protein, not the TB-500 fragment, but no efficacy RCT (evidence level: preclinical efficacy, Phase 1 safety only). Neither compound's human tissue-repair benefit has been confirmed in a controlled trial, individually or combined.

The component science is covered in the BPC-157 science guide and the TB-500 science guide.

How does Wolverine compare to GLOW and to the individual peptides?

Wolverine is the simplest of the tissue-repair blends: just BPC-157 and TB-500, with no third component. Adding GHK-Cu turns it into the GLOW blend (repair plus skin); adding GHK-Cu and KPV makes it KLOW. Choosing the two-peptide Wolverine over the separate single vials is a convenience-versus-control trade-off — a pre-blended 1:1 vial is drawn as one dose, while separate vials let BPC-157 and TB-500 run on independent schedules.

For the full side-by-side of the two peptides, see BPC-157 vs TB-500.

Why verify a Wolverine vial, and where can a two-peptide blend go wrong?

A Wolverine vial is worth verifying because even a two-peptide blend can be clean overall yet short one component. A certificate reports a single whole-vial HPLC purity — how clean the material is — but that number can read above 99% while one peptide is underdosed, so the verifiable signals are per-component: identity (mass spectrometry confirming both BPC-157 and TB-500 are present) and net content (tested milligrams versus label, for each). In a 1:1 blend, an imbalance is the quiet failure mode — a vial that delivers the BPC-157 it claims but half the TB-500 still "contains both." Peptigrity's independent lab-test database tracks both dimensions; learn to read them in how to read peptide lab test results.

How does Peptigrity verify a Wolverine vial?

Peptigrity verifies a Wolverine vial through four independent measurements from an independent third-party lab: LC-MS identity confirming both BPC-157 and TB-500 are present, HPLC-UV purity for the whole vial, per-component net content (tested versus labelled milligrams for each peptide), and endotoxin testing. Confirming the 1:1 balance is the point — the pairing only works as intended if both peptides are actually at label strength. Peptigrity collects independent third-party Certificates of Analysis for Wolverine from shops' official channels and verifies each for authenticity before publishing; because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly, and a community-funded Testing Grant to purchase and test vials anonymously is in development. The methodology and shop trust-score weighting are documented in how we calculate trust scores; the broader process is in the how to test peptides hub and the testing labs directory. For sourcing each component, see where to buy BPC-157 and where to buy TB-500.

How do you dose the Wolverine (BPC-157 + TB-500) blend?

In a fixed 1:1 Wolverine vial you set the dose of one peptide and the other follows automatically, since both are present in equal amounts. A common research-planning approach reconstitutes a 20 mg vial (10 mg of each) and draws a single daily dose; the alternative is separate vials, dosing BPC-157 daily and TB-500 on a twice-weekly loading schedule. The dedicated BPC-157 + TB-500 calculator handles the blend math, and the Wolverine stack dosing guide walks through both formats. No clinical dosing protocol exists for the combination; every figure is community-derived from single-compound research, not a validated regimen.

What is the regulatory status of Wolverine's components?

…as of August 2026, and Wolverine is sold strictly as a research-use-only compound. In April 2026 the FDA removed both peptides from its 503A Category 2 bulk-substances list because the nominations had been withdrawn by the nominators — an administrative removal that did not add them to Category 1 or authorise pharmacy compounding, leaving them in a regulatory gray zone — neither prohibited nor authorised for pharmacy compounding, with no FDA-approved product and no USP monograph. At its July 23–24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted to recommend both BPC-157 and TB-500 (8–6–1 each) for the 503A compounding list — recommendations the FDA's own reviewers had opposed in their pre-meeting briefing. The votes are advisory only; the FDA has not finalized them, and formal rulemaking is not expected before 2027. Both BPC-157 and TB-500 are prohibited by the World Anti-Doping Agency (BPC-157 under S0; TB-500/thymosin β4 under S2.3, Growth Factors), so the Wolverine blend is banned in competitive sport.